TY - JOUR
T1 - Intra-arterial therapies for hepatocellular carcinoma
T2 - Where do we stand?
AU - Liapi, Eleni
AU - Geschwind, Jean Francois H.
N1 - Funding Information:
Acknowledgement: This educational review is part of a series, ‘‘Emerging Therapeutic Approaches to Hepatocellular Carcinoma,’’ which has been supported by an educational grant from Onyx Pharmaceuticals/Bayer Healthcare Pharmaceuticals.
Copyright:
Copyright 2010 Elsevier B.V., All rights reserved.
PY - 2010/5
Y1 - 2010/5
N2 - Purpose and Design: Intra-arterial therapies for unresectable hepatocellular carcinoma (HCC) consist of a catheter-based group of treatments where therapeutic and/or embolic agents are intra-arterially directed to target tumors. Here we review these therapies, which may be classified into embolotherapy/chemotherapy-based and radiotherapy-based treatments. Embolotherapy/chemotherapy-based treatments include transcatheter arterial embolization, transarterial chemoembolization, transcatheter arterial chemoeinfusion, and chemoembolization with drug-eluting beads. Radiotherapy-based treatments include radioembolization with yttrium-90 and injection of iodine-131-labeled lipiodol. Results and Conclusion: Interpretation of the results of clinical trials as well as implementation of meta-analyses involving the efficacy of intra-arterial therapies for unresectable HCC has been challenging and difficult to perform. The levels of evidence for treatment recommendations in oncology provide a common framework to understand the current status of intra-arterial therapies for HCC. Here we use an evidence-based approach to critically review and comprehend the current role and future potential of intra-arterial therapies in unresectable HCC.
AB - Purpose and Design: Intra-arterial therapies for unresectable hepatocellular carcinoma (HCC) consist of a catheter-based group of treatments where therapeutic and/or embolic agents are intra-arterially directed to target tumors. Here we review these therapies, which may be classified into embolotherapy/chemotherapy-based and radiotherapy-based treatments. Embolotherapy/chemotherapy-based treatments include transcatheter arterial embolization, transarterial chemoembolization, transcatheter arterial chemoeinfusion, and chemoembolization with drug-eluting beads. Radiotherapy-based treatments include radioembolization with yttrium-90 and injection of iodine-131-labeled lipiodol. Results and Conclusion: Interpretation of the results of clinical trials as well as implementation of meta-analyses involving the efficacy of intra-arterial therapies for unresectable HCC has been challenging and difficult to perform. The levels of evidence for treatment recommendations in oncology provide a common framework to understand the current status of intra-arterial therapies for HCC. Here we use an evidence-based approach to critically review and comprehend the current role and future potential of intra-arterial therapies in unresectable HCC.
UR - http://www.scopus.com/inward/record.url?scp=77952084899&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=77952084899&partnerID=8YFLogxK
U2 - 10.1245/s10434-010-0977-4
DO - 10.1245/s10434-010-0977-4
M3 - Review article
C2 - 20405328
AN - SCOPUS:77952084899
SN - 1068-9265
VL - 17
SP - 1234
EP - 1246
JO - Annals of surgical oncology
JF - Annals of surgical oncology
IS - 5
ER -